SCHEDULE 13G/A: Vanguard Group Discloses Reduced Passive Stake in Immunic Inc Below 5%
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.35% in Immunic Inc as of December 31, 2024.
Summary
- The Vanguard Group, a Pennsylvania-based investment adviser, filed an Amendment No. 2 to its Schedule 13G regarding its holdings in Immunic Inc.
- As of December 31, 2024, The Vanguard Group beneficially owned an aggregate of 3,923,763 shares of Immunic Inc's Common Stock.
- This ownership represents 4.35% of Immunic Inc's outstanding common stock.
- The Vanguard Group holds sole dispositive power over 3,891,896 shares and shared dispositive power over 31,867 shares.
- The firm reported no sole or shared voting power over these shares.
- The filing confirms that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Immunic Inc.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing passive ownership, thus it carries a neutral sentiment. It provides no positive or negative operational or financial news about the issuer.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding Immunic Inc's future outlook.
Industry Context
This filing is a routine disclosure by a large institutional investor, The Vanguard Group, indicating its passive ownership stake in Immunic Inc. It reflects a standard portfolio management activity rather than a strategic industry move or a direct commentary on Immunic Inc's operational performance or industry position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming no intent to influence control. The reduction below 5% might be noted by some investors but is not inherently positive or negative.
- Company Management: Awareness of a large, passive institutional holder's position, which is a routine aspect of public company oversight.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which required the filing of this statement (reporting period end date). |
| 01/30/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Immunic Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.